| abstract |
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, which are oxazole compounds of formula 1, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition. |